WVP
ISEE

Worth Venture Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Worth Venture Partners’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,500
Closed -$558K – 221
2022
Q4 		$546K Buy
+25,500
New +$544K 0.32% 75

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Worth Venture Partners's ISEE Position: Q1 2023 in Review

Worth Venture Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2023, closing a stake of 25,500 shares — an estimated $558K sold.

Worth Venture Partners first reported a position in ISEE in Q4 2022 and held it in 1 quarter. The position peaked at $546K in Q4 2022. 223 funds tracked by Wall St. Rank hold ISEE as of Q1 2023.

  • Worth Venture Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Worth Venture Partners sold 25,500 IVERIC bio, Inc. Common Stock shares in Q1 2023, an estimated $558K.
  • Worth Venture Partners first reported a position in IVERIC bio, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Worth Venture Partners's IVERIC bio, Inc. Common Stock position peaked at $546K in Q4 2022.
  • 223 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2023.

Based on Worth Venture Partners's 13F filing for Q1 2023, filed 15 May 2023.